Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemocentryx Inc (NQ: CCXI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chemocentryx Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop
Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Reverse Course, Investors Look at Flip Side of Economic Data
While a lackluster April jobs report initially sunk stocks this morning, the indexes are bouncing back as investors speculate that the disappointing data could mean the continuation of easy policies... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Yield10 Bioscience (NASDAQ:YTEN) stock increased by 20.74% to $10.36 during Friday's regular session. As of 12:30 EST, Yield10 Bioscience's stock is... 
Via Benzinga
Why ChemoCentryx Stock Is Cratering Again Today
Investors aren't optimistic after an FDA advisory committee vote for avacopan. 
Via The Motley Fool
Exposures Product Safety
Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide
Midway through trading Friday, the Dow traded up 0.45% to 34,705.48 while the NASDAQ rose 1.35% to 13,816.46. The S&P also rose, gaining 0.77% to 4,233.93. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Why ChemoCentryx Shares Are Plunging Today
ChemoCentryx (NASDAQ: CCXI) shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated... 
Via Benzinga
Exposures Product Safety
Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April
Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
56 Stocks Moving In Friday's Mid-Day Session
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges
Yesterday, the FDA’s Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for ChemoCentryx Inc... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021
Upgrades Loop Capital upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Hold to Buy. In the first quarter, Roku showed an EPS of $0.54, compared to $0.45 from... 
Via Benzinga
ChemoCentryx Stock Loses Half Its Value; Is This The Final Nail For Its Drug?
A panel of experts was split Thursday on whether to recommend approval for ChemoCentryx's autoimmune disease drug — and CCXI stock plummeted Friday. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Friday
Stifel boosted Wayfair Inc. (NYSE: W) price target from $200 to $280. Wayfair shares rose 1.7% to $290.91 in pre-market trading. RBC Capital raised ViacomCBS Inc. (NASDAQ: VIAC... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5... 
Via Benzinga
Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate
The FDA’s Arthritis Advisory Committee voted 10 for and 8 against the approval of ChemoCentryx Inc’s (NASDAQ: CCXI) investigational drug... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
CHEMOCENTRYX SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ChemoCentryx, Inc. - CCXI
From Kahn Swick & Foti, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
ChemoCentryx Investors With Losses Greater Than $100,000 - Kehoe Law Firm, P.C. Securities Class Action Investigation
Class Action Investigation On Behalf Of ChemoCentryx Investors With Significant Losses 
Via EIN Presswire
Topics Fraud Lawsuit
Exposures Financial Legal
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – CCXI
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ChemoCentryx, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.